Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia.

Autor: Kambara T; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan. kasugarianjp@gmail.com., Shibata R; Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, 466-8550, Japan. rshibata@med.nagoya-u.ac.jp., Sakamoto Y; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan., Sakaguchi T; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan., Osanai H; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan., Nakashima Y; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan., Asano H; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan., Murohara T; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Ajioka M; Department of Cardiovascular Medicine, Tosei General Hospital, Seto, Japan.
Jazyk: angličtina
Zdroj: BMC research notes [BMC Res Notes] 2024 Mar 01; Vol. 17 (1), pp. 60. Date of Electronic Publication: 2024 Mar 01.
DOI: 10.1186/s13104-024-06726-7
Abstrakt: Objective: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH inhibitor treatment was initiated in 32 patients with chronic HF complicated by renal anemia and were followed up for 3 months.
Results: Hematocrit and hemoglobin levels markedly improved 3 months after HIF-PH inhibitor treatment. However, levels of NT-proBNP, which is an indicator of HF, did not decrease considerably. Based on the rate of change in NT-proBNP, we divided the patients into "responder" and "non-responder" groups. The results showed that considerably more patients had a ferritin level of less than 100 ng/mL in the non-responder group at baseline. There were substantially more patients with TSAT of less than 20% in the non-responder group at 1 month after HIF-PH inhibitor treatment. The cut-off values to maximize the predictive power of ferritin level at baseline and TSAT value at 1 month after treatment were 41.8 ng/ml and 20.75. HIF-PH inhibitor treatment can be expected to be effective for improving both anemia and HF if ferritin≥41.8 ng/ml at baseline or TSAT≥20.75 at 1 month after treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje